CT/NG Testing Market Growth Accelerated by Point-of-Care Testing and Increasing Awareness of Sexual Health Worldwide

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global CT/NG Testing Market- (By Product (Assays & kits, Instruments/Analyzers), By Test Type (Laboratory, Point-of-care testing), By Technology (INAAT, PCR, Immunodiagnostics, Others), By End-User (Diagnostics & Laboratories, Hospitals & Clinics, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global CT/NG Testing Market is valued at US$ 1.65 Bn in 2022, and it is expected to reach US$ 3.27 Bn by 2031, with a CAGR of 8.1% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1984

Chlamydia, a common sexually transmitted infection (STI), is caused by the bacterium Chlamydia trachomatis. While often asymptomatic in women, untreated infections can lead to serious reproductive health complications, including pelvic inflammatory disease (PID), which may result in infertility, ectopic pregnancy, and chronic pelvic pain. Similarly, gonorrhoea is an STI caused by Neisseria gonorrhoeae, with a higher prevalence observed among young adults. Populations at increased risk include individuals with multiple sexual partners, those already infected with other STIs, men who have sex with men (MSM), and sex workers.

The increasing incidence of sexually transmitted infections, coupled with rising awareness and supportive government initiatives aimed at early detection and treatment, are key factors contributing to the growth of the Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) diagnostics and treatment market.

List of Prominent Players in the CT/NG Testing Market:
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Hologic, Inc. (US),
• Thermo Fisher Scientific Inc. (US),
• Abbott Laboratories (US),
• Bio-Rad Laboratories, Inc. (US),
• Siemens Healthineers AG (Germany),
• Danaher (US),
• Becton,
• Dickinson and Company (US)

Market Dynamics:
Drivers-
The CT/NG testing market is experiencing significant growth potential, driven by government initiatives, funding programs, and strategic support aimed at fostering innovation and technological advancement. These financial incentives empower organizations to invest in research and development, expand infrastructure, and develop advanced diagnostic solutions. By improving access to funding, manufacturers are better positioned to drive innovation in CT/NG testing, resulting in advancements in disease detection, monitoring, and personalized treatment approaches. For instance, during National STD Awareness Week in April 2022, Chiricahua Community Health Centers, Inc. (CCHCI) announced a partnership with The Body Agency Collective (TBAC) and Visby Medical, Inc. to enhance sexually transmitted infection (STI) diagnostics and treatment capabilities.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Challenges:
The overall cost of CT/NG (Chlamydia trachomatis/Neisseria gonorrhoeae) testing is significantly influenced by variable expenses related to essential reagents, specialized instruments, and vendor-defined setup fees. Additional operational costs-such as equipment maintenance, insurance, laboratory oversight, and administrative expenses including rent and office space-further elevate total expenditure. As a result, only well-funded institutions, such as large hospitals and centralized reference laboratories, may possess the capital resources necessary to invest in high-cost diagnostic systems. Conversely, smaller laboratories, medical practices, and individual healthcare providers often face budgetary constraints, making it difficult to procure and operate high-value diagnostic equipment and analyzers. The cost of CT/NG testing kits and related instruments can range from USD 2,000 to USD 80,000, posing a considerable barrier to wider market adoption and potentially hindering the overall growth of the CT/NG testing segment.

Regional Trends:
The Asia-Pacific region is anticipated to record the highest compound annual growth rate (CAGR) over the forecast period, maintaining this momentum due to the increasing prevalence of sexually transmitted infections (STIs) in emerging economies. The expansion of educational campaigns aimed at raising awareness, coupled with strengthened governmental initiatives to enhance public health infrastructure and STI diagnostics, is expected to drive substantial growth in the CT/NG testing market across the region.

Recent Developments:
• In May 2022, - Abbott said that its Alinity m STI Assay had been approved by the FDA. The test finds and separates four common sexually transmitted diseases (STIs) at the same time. If STIs aren't addressed, they can cause serious health problems, like an increased chance of getting certain cancers or being unable to have children.
• In Oct 2022, Bio-Rad released two Exact Diagnostics molecular controls. The CT/NG Positive Run Control was designed for molecular tests of Chlamydia trachomatis and N. gonorrhoeae. The company said the STI Negative Run Control monitored the absence of Chlamydia trachomatis and Neisseria gonorrhoeae in molecular assays and could be used to detect laboratory testing errors, including contamination events while controlling for sample adequacy.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1984

Segmentation of CT/NG Testing Market-
By Product-
• Assays & kits
• Instruments/Analyzers
By Test Type-
• Laboratory,
• Point-of-care testing
By Technology-
• INAAT,
• PCR,
• Immunodiagnostics
• Others
By End-User-
• Diagnostics & Laboratories
• Hospitals & Clinics
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.